Latest News

The market wasn't impressed with the soft earnings from InBody Co.,Ltd ( KOSDAQ:041830 ) recently. We did some...

Despite posting some strong earnings, the market for HS Hwasung Co., Ltd.'s ( KRX:002460 ) stock hasn't moved much. Our...

Readers hoping to buy Yamada Corporation ( TSE:6392 ) for its dividend will need to make their move shortly, as the...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Oki Electric Industry Co., Ltd. ( TSE:6703 ) stock is about to trade ex-dividend in two days. Typically, the...

It looks like Kyoei Security Service Co., Ltd. ( TSE:7058 ) is about to go ex-dividend in the next two days. The...

MeiraGTx Holdings (MGTX) just posted its FY 2025 third quarter numbers, with revenue at US$0.4 million and a basic EPS loss of US$0.62, alongside net income excluding extra items of a US$50.5 million loss. Over recent quarters, the company has seen revenue move from US$21.4 million in Q4 2024 to US$3.7 million in Q2 2025, while quarterly basic EPS has tracked between a loss of US$0.48 and US$0.76. This sets the backdrop for the current trailing twelve month loss of US$168.7 million on US$27.4...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Takeda...

If you are wondering whether Sea's current share price reflects its true worth, the recent performance gives plenty to think about before making any decisions. The stock last closed at US$79.86, with returns of a 1.4% decline over 7 days, a 25.4% decline over 30 days, and a 39.3% decline year to date, adding to a 40.2% decline over 1 year and a 66.2% decline over 5 years. These moves come as Sea remains a focal name in e commerce and digital services, where investor sentiment can shift...

If you are wondering whether Five9's current share price still reflects its potential, the recent valuation picture gives you clear numbers to work with. The stock closed at US$15.12, with returns of a 4.3% decline over 7 days, a 15.2% decline over 30 days, a 19.6% decline year to date, a 48.4% decline over 1 year, a 77.9% decline over 3 years, and a 90.8% decline over 5 years, which may change how you think about its risk and return profile. Recent coverage has focused on how Five9 fits...

Health In Tech (HIT) has put up another busy quarter in FY 2025, with Q3 revenue of about US$8.5 million and basic EPS of US$0.008, set against a year where revenue was 55.1% higher and trailing net profit margins sat at 4.7% compared with 9.2% a year earlier. Over recent periods the company has seen quarterly revenue move from about US$5.0 million in Q2 2024 to US$4.9 million in Q4 2024, then to US$8.0 million in Q1 2025, US$9.3 million in Q2 2025 and US$8.5 million in Q3 2025. Over the same...

In March 2026, Glaukos Corporation announced the commercial launch of Epioxa, an incision-free, oxygen- and light-activated corneal cross-linking therapy for keratoconus, now available directly and via specialty distributors. By pairing this new therapy with expanded patient awareness, financial assistance, and access programs, Glaukos is aiming to tackle the long-standing underdiagnosis and undertreatment of this rare corneal disease. We’ll now examine how Epioxa’s incision-free keratoconus...

Expro announced it has delivered well testing services, including its GeoFlow™ Surface Well Testing package, for Vulcan Energy’s first Schleidberg well in the Lionheart geothermal and lithium project, working alongside VERCANA GmbH. This work embeds Expro in one of Europe’s most significant geothermal and lithium developments under the EU Critical Raw Materials Act, highlighting its long-standing geothermal expertise and emerging role in lower-carbon energy supply chains. We’ll now explore...

Fresenius SE KGaA (XTRA:FRE) has just wrapped up FY 2025 with fourth quarter revenue of €5.96b and basic EPS of €0.70, capping off a trailing twelve month run where revenue reached €22.45b and EPS came in at €1.94 by the end of Q3 2025, alongside earnings growth of 25.2% over the last year. Over recent periods the company has seen revenue move from €21.48b in the twelve months to Q3 2024 to €22.45b in the twelve months to Q3 2025, while EPS over the same stretch went from €1.55 to €1.94. This...

Earlier in March 2026, Baird named Huntington Bancshares a “Fresh Pick” while the bank continued expanding its branch network in the Carolinas, including a new flagship location in Winston-Salem. Combined with expectations for single-digit profit growth in the upcoming quarter, these moves have drawn attention to Huntington’s regional growth ambitions and lending momentum. We’ll now examine how Baird’s endorsement and Huntington’s Carolinas expansion may influence the bank’s existing...

If you are wondering whether Waste Connections at around US$157 per share looks attractively priced or stretched, the starting point is to understand what the current valuation is really implying. The stock has seen a 4.6% decline over the past week, a 5.0% decline over the past month, and is down 9.7% year to date and 18.3% over the past year, even though the 3 year and 5 year returns stand at 16.4% and 48.9% respectively. Recent coverage has focused on how the share price pullback sits...

Investors may be wondering if Permian Resources at around US$21.46 is offering good value right now, or if the easy gains are already behind it. The stock has posted returns of 7.5% over the last week, 20.6% over the past month, 49.0% year to date and 60.2% over the past year. This puts recent performance firmly on investors' radar. Recent coverage has focused on Permian Resources as an oil and gas producer in the Permian Basin, with attention on how the company is positioning itself...

Shionogi & Co., Ltd. ( TSE:4507 ) is about to trade ex-dividend in the next two days. Typically, the ex-dividend date...

Pony AI (PONY) just posted its FY 2025 third quarter numbers, with revenue at US$25.4 million and a basic EPS loss of US$0.16, while trailing twelve month figures show revenue of US$96.4 million and a basic EPS loss of US$1.05. Over recent quarters the company has seen revenue move from US$12.2 million in Q2 2024 to US$14.8 million in Q3 2024 and then to US$13.0 million, US$21.5 million and US$25.4 million in Q1, Q2 and Q3 2025 respectively, alongside quarterly basic EPS losses of US$0.33,...

If you are wondering whether FuboTV's current share price still reflects its true worth, the recent valuation checks raise some interesting questions about how the market is pricing this stock. The share price closed at US$9.66, with returns of a 30.0% decline over 7 days, 30.6% decline over 30 days, 68.9% decline year to date, 73.3% decline over 1 year, 23.3% decline over 3 years and 96.4% decline over 5 years. This sets a very specific backdrop for any valuation discussion. Recent...

QXO overview and recent share performance QXO (QXO), a distributor of roofing, waterproofing and building products across the US and Canada, has seen its share price move lower recently, with a 1-month return of a 21.8% decline and a past 3-month return of a 7.4% decline. See our latest analysis for QXO. Recent weakness in QXO’s share price, including a 3.1% 7 day and 21.8% 1 month share price decline from a last close of US$19.66, contrasts with its 40.3% 1 year total shareholder return...

Wondering if Enbridge at around its recent price of $75.49 is offering value or asking you to pay up? This article walks through what the current market price may be implying. The stock has posted returns of 1.8% over the last 7 days, 5.1% over 30 days and 14.3% year to date, with longer term returns of 25.8% over 1 year, 78.2% over 3 years and 125.8% over 5 years that many investors will want to put in context. Recent coverage of Enbridge has focused on its role as a large North American...

Why the AACR data matters for Zymeworks stock Zymeworks (ZYME) is in focus after the American Association for Cancer Research accepted an oral presentation and six abstracts covering its antibody drug conjugate pipeline, including early clinical results for ZW191 and multiple pan RAS ADC candidates. For you as an investor, this AACR presence highlights how much of Zymeworks’ current story is tied to the progress and differentiation of its proprietary platforms in difficult to treat cancers,...

Wondering if Cognex at around US$49 per share still offers value, or if the easy gains are behind it? This article walks through what the current price might imply about the company. Cognex has pulled back 1.8% over the last week and 14.8% over the last month, yet still shows a 33.6% return year to date and 61.8% over the past year, with a more modest 3.6% over three years and a 39.6% decline over five years. Recent attention has focused on Cognex as a key player in machine vision and...